Evidence map›Paper›PMID 41285846›Full record

ArticleNature communications2025

Regional and cell specific bioactivity of injectable extracellular matrix biomaterials in myocardial infarction.

Joshua M Mesfin, Van K Ninh, Miranda D Diaz, Michael B Nguyen, Alexander Chen, Raymond M Wang, Elyse G Wong, Maria L Karkanitsa, Jervaughn D Hunter, Justin Yu and 9 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Joshua M MesfinShu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-1022-8175
Van K NinhSchool of Medicine, University of California San Diego, San Diego, CA, USA.ORCID http://orcid.org/0000-0001-6017-4035
Miranda D DiazShu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA, USA.
Michael B NguyenShu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA, USA.
Alexander ChenShu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-8396-8759
Raymond M WangShu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA, USA.
Elyse G WongShu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA, USA.
Maria L KarkanitsaShu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-3474-2371
Jervaughn D HunterShu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA, USA.
Justin YuSchool of Medicine, University of California San Diego, San Diego, CA, USA.
Benjamin D BridgelalShu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA, USA.
John-Paul A PhamShu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA, USA.
Nika TaghdiriShu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA, USA.
David M CalcagnoShu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA, USA.
Colin G LuoSanford Consortium for Regenerative Medicine, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-1849-9957
Rebecca L BradenShu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA, USA.
Zhenxing FuSchool of Medicine, University of California San Diego, San Diego, CA, USA.
Kevin R KingShu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA, USA. krking@health.ucsd.edu.
Karen L ChristmanShu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA, USA. kchristman@ucsd.edu.ORCID http://orcid.org/0000-0002-6179-898X

Funding

Training In Cardiovascular Physiology & PharmacologyT32HL007444 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Ju Chen, Robert Scott Ross · 1985 to 2026
$11.1M
U of Calif, San Diego Neuroscience Microscopy ImagingP30NS047101 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GLEESON, JOSEPH G, ZHENG, BINHAI · 2003 to 2022
$9.0M
Training in Multi-Scale Analysis of Biological Structure and FunctionT32EB009380 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Andrew D. McCulloch, Padmini Rangamani · 2009 to 2026
$4.8M
Integrative Bioengineering of Heart, Vessels, and BloodT32HL105373 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHIEN, SHU, INTAGLIETTA, MARCOS · 2010 to 2019
$3.6M
Extracellular matrix hydrogels for treating ischemiaR01HL113468 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHRISTMAN, KAREN L · 2012 to 2020
$3.1M
Infusible Extracellular Matrix for Treating Myocardial InfarctionR01HL165232 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHRISTMAN, KAREN L · 2022 to 2025
$2.9M
Injectable Biomaterial for Treating Hypoplastic Left Heart SyndromeR01HL146147 · NHLBI · EMORY UNIVERSITY · PI CHRISTMAN, KAREN L, DAVIS, MICHAEL E · 2019 to 2022
$2.8M
Elucidating Cell Communication Networks during Tissue Inflammation, Fibrosis, and RegenerationDP2AR075321 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KING, KEVIN R · 2018 to 2018
$2.4M
Biological Mechanisms of the Infarct BorderzoneR01HL181539 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Kevin R King · 2025 to 2026
$1.5M
Illumina NovaSeq 6000 Sequencing SystemS10OD026929 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEPSEN, KRISTEN LYNN · 2019 to 2019
$600k
Injectable Decellularized Myocardial Matrix Hydrogel Mitigates Negative Left Ventricular Remodeling in a Chronic Myocardial Infarction ModelF31HL152686 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIAZ, MIRANDA DANAE · 2020 to 2022
$117k
Investigation of a Right Ventricle Based Decellularized Extracellular Matrix Hydrogel and Cardiac Progenitor Cells as a Treatment for Right Ventricular Heart FailureF31HL158212 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HUNTER, JERVAUGHN D · 2022 to 2023
$63k
American Heart Association (American Heart Association, Inc.) 24POST1242447NHLBI NIH HHS F31 HL152686NHLBI NIH HHS F31 HL158212NHLBI NIH HHS R01 HL113468NHLBI NIH HHS R01 HL146147NHLBI NIH HHS R01 HL165232NHLBI NIH HHS R01 HL181539NHLBI NIH HHS T32 HL007444NHLBI NIH HHS T32 HL105373NIAMS NIH HHS DP2 AR075321NIBIB NIH HHS T32 EB009380NIH HHS S10 OD026929NINDS NIH HHS P30 NS047101U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL113468U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL146147U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL165232
6 · The paper itself

Abstract

Myocardial infarction (MI) remains a global health concern. To mitigate subacute and chronic MI pathophysiology, we previously investigated a pro-reparative decellularized extracellular matrix hydrogel. Despite increasing interest in biomaterial scaffolds, single cell and spatially resolved transcriptomics have not been used to probe their therapeutic activity in the heart. Here, we utilize spatial transcriptomics and single nucleus RNA sequencing to delineate the regional and cell-specific bioactivity of extracellular matrix biomaterials. Extracellular matrix hydrogel subacute treatment in female rats induces cardiac resident macrophage preservation, fibroblast activation, and increased lymphatic, vasculature, smooth muscle, and cardiomyocyte development as well as neurogenesis. Chronic treatment in female rats elicits macrophage polarization, neurogenesis, and development of cardiomyocytes, endothelial cells, and fibroblasts. When comparing treatment timepoints, subacute administration has stronger immune modulation, while chronic administration demonstrates higher cardiac development markers. Both subacute and chronic administration are associated with fibroblast activation and vasculature development. Thus, we elucidate undiscovered therapeutic targets of an injectable extracellular matrix hydrogel, further demonstrating the potential of these biomaterials as an MI therapy.

Indexed as

Biocompatible MaterialsExtracellular MatrixMyocardial InfarctionAnimalsFemaleFibroblastsHydrogelsInjectionsMacrophagesMyocardiumMyocytes, CardiacRatsRats, Sprague-DawleyTissue ScaffoldsTranscriptomeBiocompatible MaterialsHydrogels

Identifiers

PMID41285846
PMCPMC12644877

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.